MBX Biosciences, Inc. Common Stock (MBX NASDAQ) stock market data APIs
$13.8611
-0.85(-6.1%)
as of July 14, 2025
Try our APIs with
free plan!
MBX Biosciences, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Prev. Close
13.8611
Open
13.0122
High
13.9964
Low
12.8145
52 wk Range
4.807-27.5
Market Cap
676 M
Shares Outstanding
31 854 K
EPS
-0.71
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MBX Biosciences, Inc. Common Stock data using free add-ons & libraries
Get MBX Biosciences, Inc. Common Stock Fundamental Data
MBX Biosciences, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -50 717 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MBX Biosciences, Inc. Common Stock News
New
MBX Biosciences stock maintains Market Outperform rating at JMP on strong Yorvipath launch
Investing.com - JMP Securities has reiterated its Market Outperform rating and $38.00 price target on MBX Biosciences Inc (NASDAQ:MBX), citing the strong U.S. launch of the company’s Yorvipath tre...
MBX Prepares For Phase 1 Trial In Q3 With IND Filing For Obesity Candidate MBX 4291
(RTTNews) - MBX Biosciences, Inc. (MBX), announced Monday that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for MBX 4291, its long-acting GLP-1/GIP...
MBX Biosciences submits IND for once-monthly obesity treatment
CARMEL, Ind. - MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company with a market capitalization of $347 million, has submitted an Investigational New Drug (IND) application ...
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions
CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide th...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
